BioNTech SE (BNTX) Q3 2024 Earnings Call Highlights: Revenue …
20 hours ago · BioNTech SE (NASDAQ:BNTX) reported a significant increase in total revenues for Q3 2024, reaching approximately EUR1.245 billion, up from EUR895 million in the same period last year.
BioNTech’s Q3 2024: Strong Revenue and Oncology Progress
1 day ago · BioNTech SE (BNTX) has released an update. BioNTech SE reported a strong third quarter in 2024, with revenues reaching €1.2 billion, largely driven by the successful launch of its variant ...
BioNTech SE Reports Strong Revenue Growth Amid Rising R&D …
1 day ago · BioNTech SE (BNTX) has released an update. BioNTech SE’s quarterly report for the period ending September 30, 2024, reveals a notable increase in revenue to €1,244.8 million compared to €895 ...
Cautious Outlook on BioNTech SE: Strong Q3 ... - Markets Insider
1 day ago · BioNTech SE (BNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today.Analyst Yaron Werber from TD Cowen maintained a Hold rating on the stock and has ...
BioNTech (BNTX) Beats Expectations, Gives Update on Cancer …
1 day ago · BioNTech reported better-than-expected quarterly results helped by solid sales of its variant-adapted Covid-19 vaccines.. Mainz, Germany-based BioNTech’s earnings per diluted share were €0.81 ...
BioNTech SE (BNTX) Latest Stock News & Headlines - Yahoo …
Get the latest BioNTech SE (BNTX) stock news and headlines to help you in your trading and investing decisions.
Pfizer and BioNTech Receive U.S. FDA Fast Track Designation for …
Dec 9, 2022 · NEW YORK and MAINZ, GERMANY, DECEMBER 9, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the companies have received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to …
Morgan Stanley Reaffirms Their Buy Rating on BioNTech SE (BNTX)
Oct 28, 2024 · However, on October 21, TD Cowen assigned a Hold rating to BioNTech SE (NASDAQ: BNTX). See the top stocks recommended by analysts >> BNTX market cap is currently $26.26B and has a P/E ratio of -48.46.
BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript
1 day ago · BioNTech SE (NASDAQ:BNTX) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ETCompany ParticipantsMichael Horowicz - Director, Investor...
BioNTech SE Reports Strong Q3 2024 Results | Markets Insider
1 day ago · Biontech Se Sponsored Adr ( (BNTX)) has released its Q3 earnings. Here is a breakdown of the information Biontech Se Sponsored Adr presented to its investors. BioNTech SE, a cutting-edge global ...